Provided by Tiger Trade Technology Pte. Ltd.

AKESO

106.400
-2.700-2.47%
Volume:8.45M
Turnover:918.31M
Market Cap:97.99B
PE:-86.31
High:111.500
Open:110.900
Low:105.300
Close:109.100
52wk High:156.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:2.13
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.233
ROE:-13.59%
ROA:-4.57%
PB:9.86
PE(LYR):-86.31
PS:24.26

Loading ...

HK Stocks in Focus: Innovative Drug Sector Surges on WCLC Data Boost, Analysts See Value After Pullback

Stock News
·
Sep 14

AKESO Shares Climb After WCLC Data Highlights OS Benefit of Lead Drug Versus Keytruda

Deep News
·
Sep 14

Movement Alert|AKESO Rises 3.65% in Regular Trading, Ivonescimab HARMONi-2 OS Data Presented at WCLC

Market Focus
·
Sep 14

Akeso Says Phase III HARMONi-2 Trial Shows Ivonescimab Lifts Overall Survival vs Pembrolizumab in PD-L1-Positive NSCLC

Reuters
·
Sep 13

Movement Alert|AKESO Declines 3.21% in Regular Trading, Trading at HK$90.85

Market Focus
·
Sep 11

Movement Alert|AKESO Falls 3.06% in Regular Trading, Trading at HK$97.9

Market Focus
·
Sep 07

UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts

Stock News
·
Sep 07

Hong Kong Stock Connect Biotech Surges: Dual-Antibody Outperforms Keytruda, Sector Heats Up

Deep News
·
Sep 06

Loose Fed Bets and AI Monetization Fuel Hong Kong Stocks Rally

Stock News
·
Sep 04

Daiwa Highlights AKESO's HARMONi-2 Milestone, Bolstering Case for Global NSCLC Study Success

Stock News
·
Sep 04

Movement Alert|AKESO Rises 5.73% in Regular Trading, Ivonescimab HARMONi-2 Study Achieves OS Key Secondary Endpoint Versus Keytruda

Market Focus
·
Sep 04

Akeso Reports Stable Share Capital in August 2026; Minor Decline in Outstanding Options

Bulletin Express
·
Sep 03

Movement Alert|AKESO Rises 5.3% in Regular Trading, Ivonescimab HARMONi-2 Study Achieves OS Key Secondary Endpoint

Market Focus
·
Sep 03

Akeso: Ivonescimab Shows Significant Overall-Survival Gain Versus Pembrolizumab in Phase III HARMONI-2 Trial

Bulletin Express
·
Sep 03

Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study

THOMSON REUTERS
·
Sep 03

Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial

Reuters
·
Sep 03

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc

THOMSON REUTERS
·
Sep 03

Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab

THOMSON REUTERS
·
Sep 03

Movement Alert|AKESO Falls 3.06% in Regular Trading, Interim Earnings Miss and Bispecific Antibody Controversy Continue to Weigh

Market Focus
·
Sep 01

Movement Alert|AKESO Falls 3.15% in Regular Trading, H1 Earnings Miss Expectations Amid Ongoing Bispecific Antibody Concerns

Market Focus
·
Aug 31